NON CONFIDENTIAL Forward Looking Statements 2 Statements in this presentation that are not descriptions of historical facts are forward looking statements that are based on management s current expectations and assumptio

Holbrook Kohrt, M.D., Ph.D.) to validate approach Objective of achieving drug candidate nomination by the end of 2015 23 NON CONFIDENTIAL PRS 080: Intended to Reverse Hepcidin Mediated Functional Iron Deficiency 24 PRS 080 designed to reverse hepcidin mediated anemia by mobilizing iron trapped in the body s iron storage cells Addresses patients unresponsive to ESA and iron therapies PK profile of PRS 080 designed to match hepcidin biology Iron Ferroportin Inflammation Hepcidin PRS 080 PRS 080 NON CONFIDENTIAL PRS 080: Effective in vivo Currently in Phase 1 25 Demonstrated efficacy and safety in cynos Single dose serum iron response Increased reticulocyte hemoglobin after multiple doses No adverse events in GLP tox First in man study initiated November 2014 Single dose escalation in HVs (n=48) Endpoints: Safety, MTD, PK, immunogenicity Target engagement PD effects: serum iron, ferritin, transferrin saturation, reticulocyte count, hemoglobin Final cohort of subjects planned mid 2015 Reporting of results expected 2H 2015 Serum iron response in cyno following single i.v. administration Pre dose Day 30 i.v. 150 mg/kg Day 30 s.c. 20 mg/kg Elevation of reticulocyte Hg in cyno following repeated administration Funded through Ph I by ongoing 6M EU grant 0 20 40 60 80 100 0 20 40 60 Time [h] 15 20 25 30 10 mg/kg PRS 080 10 mg/kg NGAL wt NON CONFIDENTIAL PRS 080 in Chronic Kidney Disease Market Opportunity 26 Sources: USRDS 2014 Annual Data Report (2012 numbers): Atlas of Chronic Kidney Disease and End Stage Renal Disease in the U.S ESRD Patients in 2011 A Global Perspective, Fresenius Medical Care; Artisan Healthcare Consulting market research study Hemodialysis Patients (Total 1.9M Worldwide) No anemia 18% Anemic 82% Hemodialysis Patients with Anemia (Total 1.6M Worldwide) FID 24% No FID 76% Target Functional Iron Deficient (FID) population: U.S. 80,000 EU 61,000 JP 57,000 ROW 186,000 Estimated yearly treatment costs: ~ $5,000 $10,000 We believe treating FID anemic patients has large commercial potential NON CONFIDENTIAL Anticalin Intellectual Property Safe Sound Exclusivity Drug class protected through 2020s Controlled patent filings and prior art enable broad follow on protection Unique IP for each program Freedom to Operate No third party IP identified to date for FTO on platform or therapeutic programs 27 Program (Target) CoM Patent Term cMet 2030 Hepcidin 2031 IL4Ra 2031 300 Series (IO) 2035+ NON CONFIDENTIAL Investment Highlights 28 Human PoC achieved with Anticalin platform Novel therapeutic proteins Desirable drug like properties Validation through strategic partnerships and collaborations Sanofi, Daiichi Sankyo, Zydus, Stelis, Allergan Several differentiated proprietary and partnered drug candidates advancing towards or through clinical development Potential for rich news flow in 2015 Potential milestone payments; expected clinical data; seeking new partnerships Proven management team and highly regarded Board of Directors Unique approach to Immuno oncology Solid Financial Position NON CONFIDENTIAL 29 Pieris Pharmaceuticals, Inc.

TNFRS / TNFRSL TNFRS TNFRSL Minmum: 8nm Expected: 13.4nm Stretched: 34nm Ab Ac (HC, C term) : ~15nm Ab Ac (LC, N term) : ~5nm Pieris bispecific constructs result in different distances between target binding sites Ab Ac (HC, N term) : ~5nm Ab Ac (LC, C term) : ~8nm Several Bispecific Formats to Interrogate Optimal Target Synapse NON CONFIDENTIAL Preclinical Validation of Tumor Localized Activation of CD137 (4 1BB) 22 Pastor et al, Molecular Therapy: 2011, 10: 1878 1886 Tumor targeting CD137 bispecific aptamer leads to tumor growth inhibition and survival advantage in vivo compared to combination therapy Supports Pieris bispecifics MoA Tumor specific clustering and activation of CD137 positive T cells The American Society of Gene Cell Therapy NON CONFIDENTIAL Summary of Pieris Immuno Oncology Efforts Focusing on multispecifics to address non responding patients and broaden therapeutic window compared to mAb approaches Trafficking immunomodulation to tumor microenvironment Varied geometry provides opportunity to test for optimal synapse between tumor cell and T cell Multispecifics can be mAb Anticalin fusions (like PRS 343) or Anticalin Anticalin fusions (undisclosed) Immunomodulatory engagers (like CD137) can be combined with several tumor targeting moieties, in a hub and spoke fashion Prioritization of costimulatory targets (multiple targets beyond CD137 actively pursued with Anticalins), but multiple checkpoint inhibitors also being investigated Internal and external resources (e.g.

Her2 is a poor prognostic indicator (1) Five year survival rate is 48% for Her2 negative versus 9.7% for HER2 positive tumors (2, 3) Micropapillary urothelial carcinoma subtype. Her2 amplification asscoiated with a three fold increased risk of death (4) Advanced Gastric Cancer Over expressed in 20% of cases. Overall survival of 14 months (trastuzumab + chemotheapy) (5) Ovarian cancer Overexpressed in 20 30% of cases of ovarian cancer Her2 is a poor prognostic indicator (Median survival of 15.7 months for HER2 high versus 32.8 months for HER2 normal) (6) 1 Hansel et al, Am J clin Pathology: 2008, 130: 274 281 2 Sato K et al, Cancer: 1992, 70: 2493 9. 3 Scholl et al, Annals of Oncology: 2001, 12: S81 S87 4 Schneider et al, Modern Pathology: 2014, 27: 758 764 5 Bang et al, Lancet: 2010, 28: 687 97 6 Berchuck et al, Cancer Res: 1990, 50:4087 91 14 NON CONFIDENTIAL HER2 has Restricted Expression in Normal Tissue Favorable tissue expression profile for immunotherapy approach Low level of HER2 expression on healthy epithelial cells (1) Receptor density range observed in tumor tissue will allow Pieris to interrogate the level of expression required for optimal activity 15 1 Press et al 1990, Oncogene. 5: 953 962 (2) 2 Protein Atlas http://www.proteinatlas.org/ENSG00000141736 ERBB2/tissue NON CONFIDENTIAL CD137 Expression is Localized in Tumor Microenvironment In tumor models there are high levels of CD137 on intratumoral CD4 and CD8 T cells Existing TIL population primed for response to CD137 agonist 16 NON CONFIDENTIAL 17 Anticalins Activate T Cells By CD137 Cross Linking 2nM 9nM 23nM 77nM 50nM 140nM ~1 M Representative CD137 specific Anticalins Control Control NON CONFIDENTIAL Donor A Capture 0 100 200 300 400 500 S0575.01L03 S0575.01O13 S0575.02K12 S0575.01F03 S0575.01J04 S0575.04J10 S0565.12D24 Concentration AC [ g/ml] Donor A Solution 0 100 200 300 400 500 S0575.01O13 S0575.02K12 S0575.01F03 S0575.01J04 S0575.01L03 S0575.04J10 S0565.12D24 Concentration AC [ g/ml] NON CONFIDENTIAL CD137 Targeting Anticalin Has Demonstrated Agonistic Properties Lead CD137 engager Anticalin identified Affinity: KD hCD137 = 2nM Non competitive CD137 engagement preserves ligand binding capability to CD137L Leads to T cell activation in ex vivo human donor cell assay 18 IL 2 production Assay (3d in culture) CD137 Ac (J10) Control NON CONFIDENTIAL HER2 CD137 Bispecific Formats Retain Target Binding Capacity 19 HER2 CD137 Ac Bispecific formats behave similarly to CD137 and HER2 building blocks Simultaneous target engagement confirmed for bispecific formats NON CONFIDENTIAL HER2 CD137 Bispecific Formats Exhibit Good Biophysical Properties 20 CD137 HER2 IgG4 (HC, N term) CD137 HER2 IgG4 (LC, C term) CD137 HER2 IgG4 (LC, N term) CD137 HER2 IgG4 (HC, C term) Constructs stable after one week in PBS at 37 C no change in SEC profile observed Stability in human plasma also confirmed using a dual binding ELISA NON CONFIDENTIAL Bispecific Geometry May Create Different Pharmacodynamic Effects 21 13.4 nm e.g.

A. et al., PloS One 2013 8(4):e60031. 3 Melero, I. et al., Eur J Immunol 1998 Mar; 28(3):1116 1121. 4 Ye, Z. et al., Nat Med 2002 Apr; 8(4):343 348. 5 Zhang, H. et al., Mol Canc Ther 2006 Jan; 5(1):149 155. 6 Yang, Y. et al., Canc Res 2007 Mar 1; 67(5):2339 2344. 7 Kohrt, H. et al, J Clin Invest. 2012 Mar;122(3):1066 75. NON CONFIDENTIAL CD137 Targeting mAbs Struggling To Find a Therapeutic Window Several early stage clinical trials with CD137 mAbs have been terminated Doses of systemic CD137 mAbs required for T cell activation have led to toxicity TNFR activation requires receptor clustering Bivalent mAbs shown to depend on Fc receptor interaction (1, 2) Fc receptor interaction is a random process which takes place throughout the body and not just at the tumor Most recent trials initiated with CD137 mAbs are focusing on NK cell activation When used at low dose in combination with, e.g., rituximab or cetuximab, may enhance ADCC activity through NK cell activation While this approach may work in defined populations, it may not take full advantage of CD137 role in T cell activation 13 1 Bulliard, Y. et al., J Exp Med 2013 Aug 26; 210(9):1685 1693 2 Bulliard, Y. et al., Immunol Cell Biol 2014 Jul; 92(6):475 480 NON CONFIDENTIAL Current HER2 Targeted Therapies Leave an Umet Need Several Solid Tumors With Upregulated HER2 Expression Not Adequately Addressed with Current Therapies Bladder cancer Overexpressed in 36% cases.

(HER2) Tumor Cell T Cell Perceived costimulatory T cell engagement in tumor environment Costimulatory signal Primary TcR signal Activation Proliferation Survival CD137 No signalling Her2 Protein Engineering Aspects Target Biology Aspects NON CONFIDENTIAL CD137 is a TNFR Costimulatory IO Target Validated marker for tumor reactive T cells in man (1) Anti CD137 mAbs improve the expansion of CD8+ melanoma TIL in adoptive T cell therapy (2) In mouse tumor model, forced tumor expression of CD137L (3) or anti CD137 scFv (4,5,6) leads to tumor elimination in T cell and NK cell dependent manner In clinical CAR T, inclusion of CD137 downstream signaling has proven key to success CD137 costimulation in T cells shown to lead to higher persistence, proinflammatory cytokine release and more effective tumor cell killing CD137 costimulation in NK cells shown to improve therapeutic response in mouse models (7) and currently translated to clinical trials 12 1 Ye, Q. et al., Clin Canc Res: 2014 Jan 1; 20(1):44 55. 2 Chacon, J.

PRS NN n.d. Ophthalmology PRS NN n.d. Ophthalmology Sanofi Group n.d. Sept 2010 Initiation Daiichi Sankyo n.d. April 2011 Initiation n.d. = not disclosed Pipeline Overview PRS 343 CD137/HER2 IO PRS 300 other n.d IO Daiichi Sankyo n.d. April 2011 Initiation NON CONFIDENTIAL Pieris Announced A Novel IO Program on May 19 10 NON CONFIDENTIAL PRS 343: CD137 HER2 Bispecific Member of PRS 300 Series Several Bispecific Formats Under Preclinical Evaluation 11 CD137 Ac trastuz. deriv.

IP, multispecifics, inhalation Alternative mechanism to advance several programs Retain commercialization rights in major markets Industry validation Cash flow upfront and milestone payments NON CONFIDENTIAL NON CONFIDENTIAL 9 PRS 080 Hepcidin Anemia PRS 060 IL4Ra Asthma Discovery Preclinical Phase 1 Target(s) 1 Indication PRS 110 cMet Oncology PRS NN n.d. n.d.

Holbrook Kohrt, M.D., Ph.D, joins as IO Advisor for Translational Medicine AUD $500k Grant with University of Melbourne for anti IL4Ra asthma progam (PRS 060) Appointment of Jean Pierre Bizzari, M.D., to Board of Directors Presentation of preclinical data on CD137 based IO multispecifics Recent Key Achievements NON CONFIDENTIAL NON CONFIDENTIAL Anticalins are Re purposed Human Therapeutic Proteins 6 Anticalin in complex with a small molecule (Y DTPA) Anticalin bound to the Hepcidin peptide Anticalin bound to the CTLA4 protein Anticalins are a novel class of therapeutic proteins, derived from lipocalins Small and simple make up Individual derivatives can be generated that bind to a broad range of targets lipocalin Differentiating Features Human derived Natural binding molecule Non immunogenic High affinity and specificity Systemic delivery Tunable pharmacokinetics Local delivery (e.g., inhalation) Versatile bispecifics multispecifics Protein Class Exclusivity Positive Freedom to Operate Landscape Anticalins Share Several Other Features with mAbs yet are Highly Differentiated 7 Monoclonal Antibodies (mAbs) are highly successful drugs Anticalins share many of the beneficial properties of mAbs yet are highly differentiated Antibody Anticalin Safety Related Efficacy Related IP Related NON CONFIDENTIAL Commercialization Strategy Multiple Shots on Goal: Partnered Proprietary 8 Pieris selects target, funds all costs Shared investment, shared ownership Fully Proprietary Co Dev Partner selects target, funds all costs Fully Partnered Immuno oncology, anemia, respiratory: strong networks High barriers to entry: e.g.

The Corporation (OTC:PIRS) Strong pipeline NON CONFIDENTIAL 4 Pieris Pharmaceuticals, Inc. The Corporation (OTC:PIRS) Solid Financial Position $43.8M in licensing milestone payments since inception $14.1M in non dilutive grants since inception $83.4M total capital raised from investors Went public in Dec 2014 through reverse merger Raised gross proceeds of $13.6M in a private placement transaction straight common stock at $2.00 $13.2M in cash as of March 31, 2015 As of 5/12/15, institutional investors collectively owned more than 65% of PIRS common shares Ally Bridge Group, Forbion Capital, Gilde, GLSV, Lombard Odier, Novo Nordisk, Sphera Funds, Zydus Cadila, and OrbiMed Advisors (23%) CEO, CSO, Head of Discovery, Head of BD formerly at MorphoSys, a German biotech success story with market cap in excess of $1.5 billion Top caliber Board of Directors Former Sanofi, Celgene and Chiron executives; Chairman from OrbiMed Highly experienced leadership team 5 November 2014 through May 2015 Ph I study initiated for anti hepcidin anemia program (PRS 080) Private Placement ($13.6 M) Public Listing (OTC Markets) Dr.

The forward looking statements included in this presentation speak only as of the date hereof, and except as required by law, we undertake no obligation to update publicly any forward looking statements for any reason after the date of this presentation to conform these statements to actual results or to changes in our expectations. NON CONFIDENTIAL 3 Clinical stage R D company developing first in class biologics Proprietary Anticalin technology Highly differentiated next generation therapeutic proteins Superior drug like properties Strong patent position and no 3 rd party IP identified to date for FTO Clinical activity, lack of immunogenicity in cancer patients Proprietary pipeline in Immuno Oncology, Immunology, Anemia and Respiratory Proven track record for successful collaborations with Pharma Pieris Pharmaceuticals, Inc.

In light of these risks, uncertainties and assumptions, the forward looking statements regarding future events and circumstances discussed in this report may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward looking statements. You should not rely upon forward looking statements as predictions of future events.

In some cases, you can identify forward looking statements by terminology including anticipates, believes, can, continue, could, estimates, expects, intends, may, plans, potential, predicts, projects, should, will, would or the negative of these terms or other comparable terminology. Factors that could cause actual results to differ materially from those currently anticipated include, without limitation, risks relating to the results of our research and development activities, including uncertainties relating to the discovery of potential drug candidates and the preclinical and clinical testing of our drug candidates; the early stage of our drug candidates presently under development; our ability to obtain and, if obtained, maintain regulatory approval of our current drug candidates and any of our other future drug candidates; our need for substantial additional funds in order to continue our operations and the uncertainty of whether we will be able to obtain the funding we need; our ability to retain or hire key scientific or management personnel; our ability to protect our intellectual property rights that are valuable to our business, including patent and other intellectual property rights; our dependence on third party manufacturers, suppliers, research organizations, testing laboratories and other potential collaborators; competition in our industry; regulatory developments in the U.S. and foreign countries; as well as those risks more fully discussed in the Risk Factors section of our Current Report on Form 8 K filed with the SEC on December 18, 2014, the Company s annual report on Form 10 K for the fiscal year ended December 31, 2014, the Company s quarterly reports on Form 10 Q, and the other reports we file with the SEC.

May 19, 2015 Pieris Pharmaceuticals, Inc. (OTC:PIRS) UBS Global Healthcare Conference 2015 Stephen S. Yoder President CEO Exhibit 99.1 NON CONFIDENTIAL Forward Looking Statements 2 Statements in this presentation that are not descriptions of historical facts are forward looking statements that are based on management s current expectations and assumptions and are subject to risks and uncertainties.

Lise Meitner Strasse 30 85354 Freising Germany Tel.: +49 (0) 8161 1411 400 Fax: +49 (0) 8161 1411 444 info pieris.com www.pieris.com